ClinicalTrials.gg
RecruitingNCT07287137CIRV2Updated Nov 2, 2026

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

A Phase 4 interventional study of Pfizer-BioNTech mRNA COVID-19 vaccine and Novavax recombinant protein vaccine in COVID -19, COVID - 19 and COVID 19, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 2, 2026Now RecruitingPrimary outcomes revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Planned enrollment
790th of 1,322
54 · median 92
Started
2025
with 45 others
Phase 4
60 of 1,860
6 open now
Primary completion
2027-09
later than 139 of 208 live
Registered
1,828th of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 790th largest by planned enrollment of the 1,322 interventional ones that give a count, is one of 46 that started in 2025, is one of 60 in phase 4, reaches primary completion later than 139 of the 208 other live ones, and was the 1,828th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

114 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2026 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.

Read the detailed description

The goal of the Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) study is to conduct, on a yearly basis, direct comparisons of immunogenicity and reactogenicity of the most recent versions of FDA-approved vaccines for COVID-19 and/or influenza. Studies will be conducted on individuals that are FDA eligible to receive these vaccines and do not have a medical condition that severely impairs their immune system. For 2026, the study will directly compare the immunogenicity and reactogenicity of the 2026 Novavax recombinant COVID-19 vaccine with the 2026 Pfizer/BioNTech mRNA COVID-19 vaccine.

03

Conditions studied

  • COVID -19
  • COVID - 19
  • COVID 19
  • Influenza
  • Respiratory Virus
  • Respiratory Viruses
  • Respiratory Virus Infection
  • Respiratory Virus Infections

Keywords

  • COVID-19 vaccine
  • Influenza vaccine
  • Respiratory virus vaccine
  • Immunogenicity
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-79 years old
  2. Have a history of any of the following risk factors for severe COVID:

    Current:

    • Age > 65 years old
    • Physical inactivity (defined as \<150 mins of moderate activity per week or \<75 mins of vigorous activity per week)
    • with ≥ 500 cells/ul
    • Smoker
    • Obesity with ≥ 30 and \< 40

    History of:

    • Asthma
    • Depression or other mood disorder
    • Schizophrenia spectrum disorder
    • Cerebrovascular disease
    • Heart failure
    • Coronary artery disease
    • Cardiomyopathy
    • Pulmonary embolism
    • Pulmonary hypertension
    • Cystic fibrosis
    • Bronchiectasis
    • Interstitial Lung Disease
    • Stage I or II chronic kidney disease (Stage 1 defined as normal (> 90) but with other signs of kidney damage such as proteinuria or hematuria) (Stage 2 defined as having a glomerular filtration rate (GFR) of 60 - 89 ml/min/1.73m2)
    • Gestational diabetes
    • Type 1 diabetes with most recent HgbA1C \< 7.5%
    • Type 2 diabetes with most recent HgbA1C \< 7.5%
    • Liver disease without cirrhosis and with liver enzyme levels ( and ALT) no greater than three times the
    • Smoking
  3. Military Health System beneficiary and DEERS eligible
  4. Willing to be randomized to receive either the Novavax COVID-19 vaccine or the mRNA Pfizer-BioNTech COVID-19 vaccine
  5. Will be able to return for a clinic visit in approximately 30 days, Day 150, and be able to follow-up online for the next 9 months.

Exclusion criteria

Exclusion Criteria

  1. History of severe allergy or severe adverse reaction such as myocardial inflammation to any component of the mRNA COVID-19 vaccines or the Novavax recombinant COVID-19 vaccine
  2. Received a COVID-19 vaccine in the last 3 months.
  3. Tested positive for COVID-19 in the past 3 months.

    - Presence of fever, cough, chills, shortness of breath, runny nose, or sore throat today on day of screening/enrollment visit.

  4. Active use of immune modulating medications.

    - Defined as active use of chronic immune modulating medications such as systemic at a dose equivalence of 20 mg prednisone or greater daily for over one month, chemotherapy, cytokine inhibitors, or agents that reduce T cell or B cell numbers or function.

  5. Diagnosed with stated.

    - Defined as: presence of a disease that is actively causing severe immune suppression or history of prior splenectomy (removal of spleen).

  6. Diabetes with the most recent HgbA1C ≥ 7.5.
  7. Stage III or greater chronic kidney disease

    - Defined as estimated \< 60 ml/min/1.73m2)

  8. Obesity with a ≥ 40
  9. with a \< 500 cells/ul
  10. History of solid organ or bone marrow transplant.
  11. Active

    - Defined as any cancer that is currently being treated or has shown evidence of progression within the past year.

  12. Chronic liver disease with compensated or decompensated cirrhosis, or liver enzyme levels ( or ALT) greater than three times the .
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Active comparator
    For fall of 2026, Arm 1 of the study will be the Pfizer-BioNTech mRNA COVID-19 vac

    Arm 1 of the study will be Pfizer-BioNTech mRNA COVID-19 vaccine

    Drug: Pfizer-BioNTech mRNA COVID-19 vaccine

  • Active comparator
    For fall of 2026, Arm 2 of the study will be the Novavax recombinant protein vaccine

    Arm 2 of the study will be the Novavax recombinant protein vaccine

    Drug: Novavax recombinant protein vaccine

Interventions

  • DrugPfizer-BioNTech mRNA COVID-19 vaccine

    COVID-19 Vaccine, mRNA

  • DrugNovavax recombinant protein vaccine

    Recombinant protein vaccine

06

What researchers measure

Primary outcomes

  1. Variant-specific immune responses (Year 2 Only)

    The primary endpoint is variant-specific immune response (magnitude and breadth) to licensed recombinant and mRNA COVID-19 products administered to adult MHS beneficiaries who are eligible for a fall COVID-19 vaccine and who are not severely immunocompromised. This will include quantifying the magnitude of binding and neutralizing antibodies to the vaccine variants and to the dominant variant present 30 days and 150 days post-vaccination. Specifically, we will test neutralizing titers (defined as the inverse serum dilution causing a 50% reduction in relative light units in a pseudovirus neutralization assay) and IgG binding antibody levels (measured in arbitrary units) against the following SARS-CoV-2 variants: XFG (vaccine strain), Wuhan-1 (ancestral strain), plus the dominant circulating variant(s) circulating during the fall of 2026 and winter of 2026-2027.

    Time frame: IgG binding antibody levels and neutralizing antibody titers will be assessed on serum samples obtained just prior to vaccination, 30 days (+/- 10 days), and 150 days (+/- 10 days) after vaccination.

  2. Variant-specific immune responses (Year 1 Only)

    The primary endpoint is variant-specific immune response (magnitude and breadth) to licensed recombinant and mRNA COVID-19 products administered to healthy adult MHS beneficiaries. This will include quantifying the magnitude of binding and neutralizing antibodies to the vaccine variants and to the dominant variant present one month post-vaccination. Specifically, we will test neutralizing titers (defined as the inverse serum dilution causing a 50% reduction in relative light units in a pseudovirus neutralization assay) and IgG binding antibody levels (measured in arbitrary units) against the following SARS-CoV-2 variants: NB.1.8.1 and XFG (predominant circulating strains in fall 2025), JN.1 and LP.8.1 (vaccine strains), and Wuhan-1 (ancestral strain).

    Time frame: IgG binding antibody levels and neutralizing antibody titers will be assessed on serum samples obtained just prior to vaccination and 30 days (+/- 10 days after vaccination).

Other outcomes

  1. Vaccine reactogenicity and other incident adverse events (compared between two licensed COVID-19 platforms - recombinant and mRNA)

    For vaccine reactogenicity and other incident adverse events, we will use Fisher exact test or a Chi-square test between study arms. Any comparisons among substrata (e.g., age strata, infection histories) will use multiplicity adjustment.

    Time frame: Reactogenicity and other incident adverse events will be assessed through 9 months after vaccination.

  2. Frequency of participant-reported test positive (antigen and/or PCR) SARS-CoV-2 infections (compared between two licensed COVID-19 platforms - recombinant and mRNA) during the eight months following COVID vaccination and assessment of their symptom patte

    Frequency of participant-reported test positive infections during the eight months following COVID-19 vaccination will be compared using Fisher exact test or a Chi-square test between study arms. Any comparisons among substrata (e.g., age strata, infection histories) will use multiplicity adjustment. Frequency of self-reported COVID-19 symptom severity (% with moderate or greater severity), and duration of illness (in days), will be compared using Fisher exact test or a Chi-square test between study arms. Any comparisons among substrata (e.g., age strata, infection histories) will use multiplicity adjustment.

    Time frame: Through 9 months after vaccination.

  3. Salivary and nasopharyngeal IgG and IgA antibody levels to vaccine SARS-CoV-2 strain and dominant SARS-CoV-2 circulating strain at 30 days and 5 months post vaccination

    Salivary and nasopharyngeal IgG and IgA antibody levels to vaccine SARS-CoV-2 strain and dominant SARS-CoV-2 circulating strain at 30 days and 5 months post vaccination will be compared between the study arms using GMT and GSD. T-tests will compare responses across two SARS-CoV-2 variants (i.e., the vaccine variant and the dominant circulating variant at the time of vaccination), stratified by vaccine type and adjusted for multiple comparisons (e.g., a Tukey's adjustment). A non-parametric comparison can be used if there is non-normally distributed data despite the use of GMT, these approaches also account for multiplicity (e.g., Kruskall-Wallis with a Dunn's adjustment for multiplicity adjustment).

    Time frame: These antibody tests will be conducted on biosamples obtained just prior to vaccination and 30 days (+/- 10 days) and 5 months (+/- 10 days) after vaccination.

  4. Antigenic cartography and antibody landscapes

    Antigenic cartography and antibody landscapes may be performed by FDA collaborators to visualize antigenic drift from the vaccine with sequential variants, leveraging prior analysis approaches used by the study team. These analyses use relative differences in neutralizing antibody responses to generate two-dimensional maps (antigenic cartography) or three-dimensional landscapes that enable one to assess how antigenically similar different virus strains are to each other. Antibody landscapes are useful tools which can capture differential multiple serial antigenic exposures in comparisons of antibody titer and breadth between individuals assigned to receive the recombinant or mRNA vaccines (see examples from Wang et al., Cell Host Microbe, 2022).

    Time frame: Antigenic cartography studies may be conducted using neutralizing antibody titers obtained just prior to vaccination and 30 days (+/- 10 days) after vaccination.

  5. Quantify frequencies of spike-specific T cells, other T-cell immunity characteristics, and B cell immunity markers pre-vaccination, 30 days post-vaccination, and 5 months post-vaccination

    Quantify frequencies of spike-specific T cells, other T-cell immunity characteristics, and B cell immunity markers pre-vaccination, 30 days post-vaccination, and 5 months post-vaccination

    Time frame: 30 days (+/- 10 days) post-vaccination, and 5 months (+/- 10 days) post-vaccination

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • McLeod C, Dymock M, Flanagan KL, Plebanski M, Marshall H, Estcourt MJ, Tjiam MC, Blyth CC, Subbarao K, Mordant FL, Nicholson S, Faust SN, Wadia U, Thornton RB, Ellis Z, Mckenzie A, Marsh JA, Snelling TL, Richmond P. The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old. J Infect. 2024 Dec;89(6):106286. doi: 10.1016/j.jinf.2024.106286. Epub 2024 Sep 26. PubMed 39341401 ↗
  • National Center for Advancing Translational Sciences. Serious adverse events. Available at ht tps://toolkit.ncats.nih.gov/glossary/serious-adverse-event/; accessed 2 January 2025.
  • Wang W, Lusvarghi S, Subramanian R, Epsi NJ, Wang R, Goguet E, Fries AC, Echegaray F, Vassell R, Coggins SA, Richard SA, Lindholm DA, Mende K, Ewers EC, Larson DT, Colombo RE, Colombo CJ, Joseph JO, Rozman JS, Smith A, Lalani T, Berjohn CM, Maves RC, Jones MU, Mody R, Huprikar N, Livezey J, Saunders D, Hollis-Perry M, Wang G, Ganesan A, Simons MP, Broder CC, Tribble DR, Laing ED, Agan BK, Burgess TH, Mitre E, Pollett SD, Katzelnick LC, Weiss CD. Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history. Cell Host Microbe. 2022 Dec 14;30(12):1745-1758.e7. doi: 10.1016/j.chom.2022.10.012. Epub 2022 Oct 21. PubMed 36356586 ↗
  • Wang W, Bhushan G, Paz S, Stauft CB, Selvaraj P, Goguet E, Bishop-Lilly KA, Subramanian R, Vassell R, Lusvarghi S, Cong Y, Agan B, Richard SA, Epsi NJ, Fries A, Fung CK, Conte MA, Holbrook MR, Wang TT, Burgess TH, Pollett SD, Mitre E, Katzelnick LC, Weiss CD. Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1. J Virol. 2024 Nov 19;98(11):e0094824. doi: 10.1128/jvi.00948-24. Epub 2024 Oct 4. PubMed 39365051 ↗
  • Conner TL, Goguet E, Haines-Hull H, et al: Subclinical SARS-CoV-2 Infections and Endemic Human Coronavirus Immunity Shape SARS-CoV-2 Saliva Antibody Responses. MedRxiv 2024; doi .org/10.1101/2024.05.22.24307751.
  • Laing ED, Weiss CD, Samuels EC, Coggins SA, Wang W, Wang R, Vassell R, Sterling SL, Tso MS, Conner T, Goguet E, Moser M, Jackson-Thompson BM, Illinik L, Davies J, Ortega O, Parmelee E, Hollis-Perry M, Maiolatesi SE, Wang G, Ramsey KF, Reyes AE, Alcorta Y, Wong MA, Lindrose AR, Duplessis CA, Tribble DR, Malloy AMW, Burgess TH, Pollett SD, Olsen CH, Broder CC, Mitre E. Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers. Emerg Infect Dis. 2022 Apr;28(4):828-832. doi: 10.3201/eid2804.212037. Epub 2022 Feb 24. PubMed 35203111 ↗
  • Jackson-Thompson BM, Goguet E, Laing ED, Olsen CH, Pollett S, Hollis-Perry KM, Maiolatesi SE, Illinik L, Ramsey KF, Reyes AE, Alcorta Y, Wong MA, Davies J, Ortega O, Parmelee E, Lindrose AR, Moser M, Graydon E, Letizia AG, Duplessis CA, Ganesan A, Pratt KP, Malloy AM, Scott DW, Anderson SK, Snow AL, Dalgard CL, Powers JH 3rd, Tribble D, Burgess TH, Broder CC, Mitre E. Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers. BMC Infect Dis. 2021 Jun 9;21(1):544. doi: 10.1186/s12879-021-06233-1. PubMed 34107889 ↗
  • U.S. Food and Drug Administration. Highlights of prescribing information: COMIRNATY® (COVID-19 Vaccine, mRNA) suspension for injection, for intramuscular use. 2024. Available at ht tps://www.fda.gov/media/151707/download; accessed 2 January 2025.
  • U.S. Food and Drug Administration. Fact Sheet for healthcare providers administering vaccine: Emergency Use Authorization of Novavax COVID-19 Vaccine, adjuvanted (2024 - 2025 formula), for individuals 12 years of age and older. 2024. Available at https://www.fda.gov /media/159897/download; accessed 2 January 2025.
  • Fong Y, Huang Y, Benkeser D, Carpp LN, Anez G, Woo W, McGarry A, Dunkle LM, Cho I, Houchens CR, Martins K, Jayashankar L, Castellino F, Petropoulos CJ, Leith A, Haugaard D, Webb B, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Randhawa AK, Andrasik MP, Kublin JG, Hutter J, Keshtkar-Jahromi M, Beresnev TH, Corey L, Neuzil KM, Follmann D, Ake JA, Gay CL, Kotloff KL, Koup RA, Donis RO, Gilbert PB; Immune Assays Team; Coronavirus Vaccine Prevention Network (CoVPN)/2019nCoV-301 Principal Investigators and Study Team; United States Government (USG)/CoVPN Biostatistics Team. Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial. Nat Commun. 2023 Jan 19;14(1):331. doi: 10.1038/s41467-022-35768-3. PubMed 36658109 ↗
  • Weitzman ER, Sherman AC, Levy O. SARS-CoV-2 mRNA Vaccine Attitudes as Expressed in U.S. FDA Public Commentary: Need for a Public-Private Partnership in a Learning Immunization System. Front Public Health. 2021 Jul 16;9:695807. doi: 10.3389/fpubh.2021.695807. eCollection 2021. PubMed 34336774 ↗
  • Biggs AT, Littlejohn LF. Describing mRNA Vaccine Technology for a Military Audience. Mil Med. 2023 Mar 20;188(3-4):547-554. doi: 10.1093/milmed/usac129. PubMed 35584186 ↗
  • Marchese AM, Rousculp M, Macbeth J, Beyhaghi H, Seet BT, Toback S. The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger RNA: A Targeted Review. J Infect Dis. 2024 Aug 16;230(2):e496-e502. doi: 10.1093/infdis/jiad519. PubMed 37992183 ↗
  • Scher AI, Berjohn CM, Byrne C, Colombo RE, Colombo CJ, Edwards MS, Ewers EC, Ganesan A, Jones M, Larson DT, Libraty D, Lindholm DA, Madar CS, Maldonado CJ, Maves RC, Mende K, Richard SA, Rozman JS, Rusiecki J, Smith A, Simons M, Tribble D, Agan B, Burgess TH, Pollett SD; EPICC COVID-19 Cohort Study Group. An Analysis of SARS-CoV-2 Vaccine Reactogenicity: Variation by Type, Dose, and History, Severity, and Recency of Prior SARS-CoV-2 Infection. Open Forum Infect Dis. 2022 Jun 28;9(7):ofac314. doi: 10.1093/ofid/ofac314. eCollection 2022 Jul. PubMed 35899278 ↗
  • U.S. Food and Drug Administration. FDA Briefing Document. Vaccines and Related Biological Products Advisory Committee Meeting June 5, 2024. 2024. Available at https://www.fda.gov /media/179003/download; accessed 10 October 2024.
  • U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee June 5, 2024 Meeting Announcement. 2024. Available at https://www.fda.gov /advisory-committees/advisory-committee-calendar/vaccines-and-related-biological- products-advisory-committee-june-5-2024-meeting-announcement; accessed 10 October 2024.
  • Winkler EL, Stahlman SL, Wells NY, Chauhan AV, Hiban KM, Costello AA, Mancuso JD. COVID-19 Booster Vaccination in the U.S. Military, August 2021-January 2022. Am J Prev Med. 2023 Feb;64(2):270-274. doi: 10.1016/j.amepre.2022.07.017. Epub 2022 Aug 29. PubMed 36123230 ↗
  • Centers for Disease Control and Prevention. ACIP Evidence to Recommendations (EtR) for Use of 2024-2025 COVID-19 Vaccines in Persons ≥6 Months of Age. 2024. Available at https:// www.cdc.gov/vaccines/acip/recs/grade/covid-19-2024-2025-6-months-and-older-etr. html; accessed 10 October 2024.
  • Centers for Disease Control and Prevention. Staying Up to Date with COVID-19 Vaccines. 2024. Available at https://www.cdc.gov/covid/vaccines/stay-up-to-date.html; accessed 10 October 2024.
  • Lam ICH, Zhang R, Man KKC, Wong CKH, Chui CSL, Lai FTT, Li X, Chan EWY, Lau CS, Wong ICK, Wan EYF. Persistence in risk and effect of COVID-19 vaccination on long-term health consequences after SARS-CoV-2 infection. Nat Commun. 2024 Feb 26;15(1):1716. doi: 10.1038/s41467-024-45953-1. PubMed 38403654 ↗
  • Richard SA, Scher AI, Rusiecki J, Byrne C, Berjohn CM, Fries AC, Lalani T, Smith AG, Mody RM, Ganesan A, Huprikar N, Colombo RE, Colombo CJ, Schofield C, Lindholm DA, Mende K, Morris MJ, Jones MU, Flanagan R, Larson DT, Ewers EC, Bazan SE, Saunders D, Maves RC, Livezey J, Maldonado CJ, Edwards MS, Rozman JS, O'Connell RJ, Simons MP, Tribble DR, Agan BK, Burgess TH, Pollett SD; EPICC COVID-19 Cohort Study Group. Decreased Self-reported Physical Fitness Following SARS-CoV-2 Infection and the Impact of Vaccine Boosters in a Cohort Study. Open Forum Infect Dis. 2023 Nov 17;10(12):ofad579. doi: 10.1093/ofid/ofad579. eCollection 2023 Dec. PubMed 38130596 ↗
  • Hone E, Pollett SD, Richard SA, et al, editors. The Molecular Epidemiology and Congregate Transmission Dynamics of Acute Respiratory Infections (ARIs) at United States Naval Academy (USNA) during Plebe Summer. Poster #113. Military Health System Research Symposium; 2024; Kissimmee, FL.
  • Absolute and Relative Morbidity Burdens Attributable to Various Illnesses and Injuries Among Active Component Members of the U.S. Armed Forces, 2023. 2024. Available at https://www. health.mil/News/Articles/2024/06/01/MSMR-Health-Care-Burden-Active-Component; accessed 10 October 2024.
  • Absolute and Relative Morbidity Burdens Attributable to Various Illnesses and Injuries Among Non-Service Member Beneficiaries of the Military Health System, 2023. 2024. Available at https: //health.mil/News/Articles/2024/07/01/MSMR-MHS-Beneficiaries-2023; accessed 10 October 2024.
  • Taylor CA, Patel K, Pham H, Kirley PD, Kawasaki B, Meek J, Witt L, Ryan PA, Reeg L, Como-Sabetti K, Domen A, Anderson B, Bushey S, Sutton M, Talbot HK, Mendez E, Havers FP; COVID-NET Surveillance Team. COVID-19-Associated Hospitalizations Among U.S. Adults Aged >/=18 Years - COVID-NET, 12 States, October 2023-April 2024. MMWR Morb Mortal Wkly Rep. 2024 Oct 3;73(39):869-875. doi: 10.15585/mmwr.mm7339a2. PubMed 39361542 ↗
  • National Center for Health Statistics. Provisional COVID-19 Mortality Surveillance. Centers for Disease Control and Prevention; 2024. Available at https://www.cdc.gov/nchs/nvss/vsrr /covid19/index.htm; accessed 10 October 2024.
  • Kasper MR, Geibe JR, Sears CL, Riegodedios AJ, Luse T, Von Thun AM, McGinnis MB, Olson N, Houskamp D, Fenequito R, Burgess TH, Armstrong AW, DeLong G, Hawkins RJ, Gillingham BL. An Outbreak of Covid-19 on an Aircraft Carrier. N Engl J Med. 2020 Dec 17;383(25):2417-2426. doi: 10.1056/NEJMoa2019375. Epub 2020 Nov 11. PubMed 33176077 ↗
  • Mease LE, Smith AM. Surveillance snapshot: A simple model estimating the impact ofCOVID-19 on lost duty days among U.S. service members. MSMR. 2021 Sep 1;28(9):17. No abstract available. PubMed 34854661 ↗
  • U.S. Department of Defense. Coronavirus: DoD Response. 2024. Available at https://www. defense.gov/Spotlights/Coronavirus-DOD-Response/; accessed 8 October 2024.
  • Absolute and relative morbidity burdens attributable to various illnesses and injuries, active component, U.S. Armed Forces, 2020. MSMR. 2021 May;28(5):2-9. No abstract available. PubMed 34155889 ↗
  • Sanchez JL, Cooper MJ, Myers CA, Cummings JF, Vest KG, Russell KL, Sanchez JL, Hiser MJ, Gaydos CA. Respiratory Infections in the U.S. Military: Recent Experience and Control. Clin Microbiol Rev. 2015 Jul;28(3):743-800. doi: 10.1128/CMR.00039-14. PubMed 26085551 ↗
  • Gray GC, Callahan JD, Hawksworth AW, Fisher CA, Gaydos JC. Respiratory diseases among U.S. military personnel: countering emerging threats. Emerg Infect Dis. 1999 May-Jun;5(3):379-85. doi: 10.3201/eid0503.990308. PubMed 10341174 ↗
09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Sep 2027, 22 months after the start.

Of 145 non-industry phase 4 interventional studies under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's planned 22 months is above that.

Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Dec 17, 2025
StartActual
Nov 12, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 28, 2026
Sites
Walter Reed National Military Medical Center is now Recruiting
Oct 28, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedVariant-specific immune responses (Year 2 Only)Time frame: IgG binding antibody levels and neutralizing antibody titers will be assessed on serum samples obtained just prior to vaccination, 30 days (+/- 10 days), and 150 days (+/- 10 days) after vaccination.
  • AddedVariant-specific immune responses (Year 1 Only)Time frame: IgG binding antibody levels and neutralizing antibody titers will be assessed on serum samples obtained just prior to vaccination and 30 days (+/- 10 days after vaccination).
Nov 2, 2026
Contact
Study contact now listed: added m•••@hjf.org · •••2067. See the current contact
Oct 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Walter Reed National Military Medical Center · Bethesda, United StatesContact added i•••@health.mil · •••8673Contact added (no phone or email listed)
Oct 28, 2026
Show all 2 updates
  1. Nov 2, 2026
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedVariant-specific immune responses (Year 2 Only)Time frame: IgG binding antibody levels and neutralizing antibody titers will be assessed on serum samples obtained just prior to vaccination, 30 days (+/- 10 days), and 150 days (+/- 10 days) after vaccination.
    • AddedVariant-specific immune responses (Year 1 Only)Time frame: IgG binding antibody levels and neutralizing antibody titers will be assessed on serum samples obtained just prior to vaccination and 30 days (+/- 10 days after vaccination).
  2. Oct 28, 2026
    Active, not recruiting→Recruiting
    Walter Reed National Military Medical Center is now Recruiting
    Contact Study contact now listed: added m•••@hjf.org · •••2067. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Walter Reed National Military Medical Center · Bethesda, United StatesContact added i•••@health.mil · •••8673Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07287137
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Collaborators
Centers for Disease Control and Prevention, Food and Drug Administration (FDA)
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Nov 12, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Marianne Spevak, BSHS
Contact
mspevak@hjf.org
240-694-2067
Edward Mitre, MD
principal investigator · Uniformed Services University of the Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion